טמו 180 מ"ג Iisrael - heebrea - Ministry of Health

טמו 180 מ"ג

perrigo israel agencies ltd - temozolomide 180 mg - capsules - temozolomide - temo capsules are indicated for the treatment of patients with malignant glioma such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy. temo capsules are also indicated as first line treatment for patients with advanced metastatic malignant melanoma. newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and subsequently as monotherapy treatment.

טמו 250 מג Iisrael - heebrea - Ministry of Health

טמו 250 מג

padagis israel agencies ltd, israel - temozolomide - קפסולות - temozolomide 250 mg - temozolomide - temozolomide - temo capsules are indicated for the treatment of patients with malignant glioma such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy. temo capsules are also indicated as first line treatment for patients with advanced metastatic malignant melanoma. newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and subsequently as monotherapy treatment.

טמו 250 מג Iisrael - heebrea - Ministry of Health

טמו 250 מג

padagis israel agencies ltd, israel - temozolomide - קפסולות - temozolomide 250 mg - temozolomide - temozolomide - temo capsules are indicated for the treatment of patients with malignant glioma such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy. temo capsules are also indicated as first line treatment for patients with advanced metastatic malignant melanoma. newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and subsequently as monotherapy treatment.

מטוג'קט 50 מג  מל תת עורי Iisrael - heebrea - Ministry of Health

מטוג'קט 50 מג מל תת עורי

tzamal bio-pharma ltd - methotrexate - תמיסה להזרקה - methotrexate 50 mg/ml - methotrexate - methotrexate - psoriasis in adult patients :because of the high risk attending its use, methotrexate is indicated only in the symptomatic control of severe recalcitrant, disabling psoriasis which is not adequately responsive to other forms of therapy, and only when the diagnosis has been established, as by biopsy and/or after dermatological consultation. rheumatoid arthritis: methotrexate can be used in the treatment of selected adults with severe rheumatoid arthritis, only when the diagnosis has been well estabished according to rheumatological standards, with inadequate response to other forms of antirheumatic therapy, including full dose nsaids and usually a trial of at least one or more disease-modifying antirheumatic drugs.juvenile idiopathic arthritis:treatment of polyarthritic forms of severe, active juvenile idiopathic arthritis in patients 3 years of age and above when the response to non-steroidal anti-inflammatory drugs (nsaids) has been inadequate

מטוג'קט 50 מג  מל תת עורי Iisrael - heebrea - Ministry of Health

מטוג'קט 50 מג מל תת עורי

tzamal bio-pharma ltd - methotrexate - תמיסה להזרקה - methotrexate 50 mg/ml - methotrexate - methotrexate - psoriasis in adult patients :because of the high risk attending its use, methotrexate is indicated only in the symptomatic control of severe recalcitrant, disabling psoriasis which is not adequately responsive to other forms of therapy, and only when the diagnosis has been established, as by biopsy and/or after dermatological consultation. rheumatoid arthritis: methotrexate can be used in the treatment of selected adults with severe rheumatoid arthritis, only when the diagnosis has been well estabished according to rheumatological standards, with inadequate response to other forms of antirheumatic therapy, including full dose nsaids and usually a trial of at least one or more disease-modifying antirheumatic drugs.juvenile idiopathic arthritis:treatment of polyarthritic forms of severe, active juvenile idiopathic arthritis in patients 3 years of age and above when the response to non-steroidal anti-inflammatory drugs (nsaids) has been inadequate

מטוג'קט 50 מג  מל תת עורי Iisrael - heebrea - Ministry of Health

מטוג'קט 50 מג מל תת עורי

tzamal bio-pharma ltd - methotrexate - תמיסה להזרקה - methotrexate 50 mg/ml - methotrexate - methotrexate - psoriasis in adult patients :because of the high risk attending its use, methotrexate is indicated only in the symptomatic control of severe recalcitrant, disabling psoriasis which is not adequately responsive to other forms of therapy, and only when the diagnosis has been established, as by biopsy and/or after dermatological consultation. rheumatoid arthritis: methotrexate can be used in the treatment of selected adults with severe rheumatoid arthritis, only when the diagnosis has been well estabished according to rheumatological standards, with inadequate response to other forms of antirheumatic therapy, including full dose nsaids and usually a trial of at least one or more disease-modifying antirheumatic drugs.juvenile idiopathic arthritis:treatment of polyarthritic forms of severe, active juvenile idiopathic arthritis in patients 3 years of age and above when the response to non-steroidal anti-inflammatory drugs (nsaids) has been inadequate

מטוג'קט 50 מג  מל תת עורי Iisrael - heebrea - Ministry of Health

מטוג'קט 50 מג מל תת עורי

tzamal bio-pharma ltd - methotrexate - תמיסה להזרקה - methotrexate 50 mg/ml - methotrexate - methotrexate - psoriasis in adult patients :because of the high risk attending its use, methotrexate is indicated only in the symptomatic control of severe recalcitrant, disabling psoriasis which is not adequately responsive to other forms of therapy, and only when the diagnosis has been established, as by biopsy and/or after dermatological consultation. rheumatoid arthritis: methotrexate can be used in the treatment of selected adults with severe rheumatoid arthritis, only when the diagnosis has been well estabished according to rheumatological standards, with inadequate response to other forms of antirheumatic therapy, including full dose nsaids and usually a trial of at least one or more disease-modifying antirheumatic drugs.juvenile idiopathic arthritis:treatment of polyarthritic forms of severe, active juvenile idiopathic arthritis in patients 3 years of age and above when the response to non-steroidal anti-inflammatory drugs (nsaids) has been inadequate

מטוג'קט 10 מ"ג /מ"ל Iisrael - heebrea - Ministry of Health

מטוג'קט 10 מ"ג /מ"ל

tzamal bio-pharma ltd - methotrexate 10 mg/ml - solution for injection - methotrexate - psoriasis:because of the high risk attending its use, methotrexate is indicated only in the symptomatic control of severe recalcitrant, disabling psoriasis which is not adequately responsive to other forms of therapy, and only when the diagnosis has been established, as by biopsy and/or after dermatological consultation. rheumatoid arthritis: methotrexate can be used in the treatment of selected adults with severe rheumatoid arthritis, only when the diagnosis has been well estabished according to rheumatological standards, with inadequate response to other forms of antirheumatic therapy, including full dose nsaids and usually a trial of at least one or more disease-modifying antirheumatic drugs.

מתוטרקסאט אבווה 20 מגמל Iisrael - heebrea - Ministry of Health

מתוטרקסאט אבווה 20 מגמל

novartis israel ltd - methotrexate - תמיסה להזרקה - methotrexate 20 mg/ml - methotrexate - methotrexate - psoriasis: methotrexate is indicated only in the symptomatic control of severe recalcitrant, disabling psoriasis which is not adequately responsive to other forms of therapy, and only when the diagnosis has been established, as by biopsy and/or after dermatological consultation. rheumatoid arthritis: methotrexate can be used in the treatment of selected adults with severe rheumatoid arthritis, only when the diagnosis has been well established according to rheumatological standards, with inadequate response to other forms of antirheumatic therapy, including full dose nsaids and usually a trial of at least one or more disease- modifying antirheumatic drugs.

מטוג'קט 50 מ"ג / מ"ל Iisrael - heebrea - Ministry of Health

מטוג'קט 50 מ"ג / מ"ל

tzamal bio-pharma ltd - methotrexate 50 mg/ml - solution for injection - methotrexate - psoriasis:because of the high risk attending its use, methotrexate is indicated only in the symptomatic control of severe recalcitrant, disabling psoriasis which is not adequately responsive to other forms of therapy, and only when the diagnosis has been established, as by biopsy and/or after dermatological consultation. rheumatoid arthritis: methotrexate can be used in the treatment of selected adults with severe rheumatoid arthritis, only when the diagnosis has been well estabished according to rheumatological standards, with inadequate response to other forms of antirheumatic therapy, including full dose nsaids and usually a trial of at least one or more disease-modifying antirheumatic drugs.juvenile idiopathic arthritis:treatment of polyarthritic forms of severe, active juvenile idiopathic arthritis when the response to non-steroidal anti-inflammatory drugs (nsaids) has been inadequate